| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
484,602 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,100,996 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
70 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  667, L.p. |
Director |
– • – |
2013-05-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,868,576 |
|
- |
|
| 14159, L.p. |
Director |
– • – |
2013-05-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
323,148 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2013-05-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,131,223 |
|
- |
|
| Baker Bros Advisors Llc |
Director |
– • • |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
I/I |
10,500 |
326,648 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
9,619 |
|
- |
|
| Mclaughlin John Peter |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
28,500 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
3,500 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
187,220 |
|
- |
|
| Gryska David W |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
22,000 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
121,450 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
13,905 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2013-05-10 |
4 |
S |
$37.17 |
$650,430 |
D/D |
(17,500) |
10,405 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2013-05-10 |
4 |
OE |
$12.76 |
$223,300 |
D/D |
17,500 |
27,905 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2013-05-09 |
4 |
B |
$33.73 |
$4,715,922 |
I/I |
138,073 |
372,860 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2013-05-08 |
4 |
B |
$33.72 |
$7,929,305 |
I/I |
233,055 |
369,522 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2013-05-07 |
4 |
B |
$33.40 |
$3,938,140 |
I/I |
117,254 |
363,887 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2013-05-01 |
4 |
AS |
$36.58 |
$73,153 |
D/D |
(2,000) |
1,077,211 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2013-05-01 |
4 |
OE |
$10.33 |
$20,660 |
D/D |
2,000 |
1,079,211 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2013-04-01 |
4 |
AS |
$35.53 |
$71,062 |
D/D |
(2,000) |
1,077,211 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2013-04-01 |
4 |
OE |
$10.33 |
$20,660 |
D/D |
2,000 |
1,079,211 |
|
- |
|
| Boerner Christopher S. |
SVP, Commercial |
• – – |
2013-03-15 |
4 |
S |
$33.61 |
$285,663 |
D/D |
(8,500) |
33,753 |
|
- |
|
| Boerner Christopher S. |
SVP, Commercial |
• – – |
2013-03-15 |
4 |
OE |
$15.10 |
$128,350 |
D/D |
8,500 |
42,253 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2013-03-11 |
4 |
S |
$31.15 |
$1,869,471 |
D/D |
(60,000) |
112,948 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2013-03-11 |
4 |
OE |
$12.00 |
$605,671 |
D/D |
50,000 |
137,504 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2013-03-07 |
4 |
S |
$30.70 |
$1,528,706 |
D/D |
(49,718) |
113,957 |
|
- |
|
1805 Records found
|
|
Page 42 of 73 |
|
|
